Pliant Therapeutics (PLRX – Research Report) received a Hold rating and price target from Needham analyst Joseph Stringer today. The ...

As Meghan’s new Netflix show airs for the first time, Tanya Gold explores the complex, heart-breaking and deeply unhealthy ...

Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q4 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to ...

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The cli ...

Environmental activist Greta Thunberg spawned a new generation of youth eager to combat climate change. Foresight narratives ...

Getting rid of the military’s top lawyers is not exactly a sign that the Trump administration wants to follow the law.

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...

Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week ...

Dr. Kelly is survived by his son, Ken, four adult grandchildren and 10 great grandchildren. In lieu of flowers, donations may ...

Pliant Technologies’ CrewCom CB2 Professional Wireless Intercom system is a full-duplex, install-friendly and feature-packed solution for small to mid-level applications requiring a reliable, great ...

The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...